Novo Nordisk is putting its soaring semaglutide sales to work, agreeing to pay up to $1.3 billion for KBP Biosciences’ phase 3 challenger to Bayer’s chronic kidney disease (CKD) drug Kerendia.Denmark’s Novo Nordisk ended last week by raising its sales outlook again, citing soaring demand for its diabetes and weight loss medicines Ozempic and Wegovy […]